ECTRIMS: European Committee for Treatment and Research in Multiple Sclerosis
Conference Coverage
Average daily step count reflects disability in MS
STOCKHOLM – Step count can be monitored remotely and correlates with measures of walking performance, cognitive...
Conference Coverage
In highly active MS, is skipping gadolinium an option?
STOCKHOLM – Though skipping contrast missed a small number of lesions, most patients would still have been classified and treated correctly.
Conference Coverage
Most patients with RIS develop MS within 10 years
STOCKHOLM – The conversion rate jumps to 87% in the presence of four risk factors at baseline.
Conference Coverage
In MS, iron-ringed lesions may add to imaging toolkit
STOCKHOLM – Brain lesions with iron rings were detected only in MRI scans of MS patients.
Conference Coverage
Ponesimod reduces annualized relapse rate, compared with teriflunomide
STOCKHOLM – The investigational MS treatment is superior to the approved drug on measures of fatigue and active...
Conference Coverage
Continuous treatment reduces risk of confirmed disability progression in MS
STOCKHOLM – The risk of confirmed disability progression appears to decrease with increasing length of continuous...
Conference Coverage
Neurologists need not discourage breastfeeding in women with MS
STOCKHOLM – For women with MS who want to breastfeed and have more active disease where early treatment resumption is warranted, the key is to...
Conference Coverage
Real-world data reveal long-lasting effects achieved with RRMS treatments
BERLIN –
Conference Coverage
Dietary sodium still in play as a potential MS risk factor
BERLIN – High-salt diets decimate Lactobacillus species, with downstream immune effects.
Conference Coverage
Breastfeeding with MS: Good for mom, too
Conference Coverage
Fatigue in MS: Common, often profound, tough to treat
BERLIN – Cognitive behavioral therapy carries the best evidence to treat MS-related fatigue.
Conference Coverage
Particular lesions early after CIS predict long-term MS disability
Conference Coverage
MS disease activity returns in one-third after fingolimod withdrawal
BERLIN – Risk factors for higher disease activity include younger age at diagnosis, shorter disease duration, and stopping more than 2 months...
Conference Coverage
Anti-MOG antibodies associated with non-MS, monophasic demyelinating disease in young children
BERLIN – Age and anti-MOG antibody status may help to predict a non-MS diagnosis.
Conference Coverage
Demyelinating diseases, especially MS, disrupt normal brain development in children